Osiris CEO steps down for 'personal reasons'

Osiris Therapeutics ($OSIR) CEO Lode Debrabandere is resigning his position after 10 years at the company, citing "personal reasons." Dwayne Montgomery, Osiris' current chief business officer, is taking over on an interim basis, the company said. Debrabandere has served as CEO since 2013 when his predecessor, Randal Mills, resigned for "personal reasons" of his own. The biotech's shares fell more than 10% on Thursday. More

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.